TH-CART-027

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameTH-CART-027
Drug Alias NameTH-CART-027TH027TH-027
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionT lymphocyte replacementsAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXinchuan Biotechnology (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXinchuan Biotechnology (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A